PROFOUND MEDICAL CORP.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | — | $16.1M | $10.7M | $7.2M |
| Cost of Revenue | — | $4.7M | $3.6M | $2.9M |
| Gross Profit | — | $11.4M | $7.0M | $4.3M |
| Gross Margin | — | 70.8% | 65.9% | 59.9% |
| Operating Expenses | ||||
| Research & Development | — | $20.6M | $17.0M | $14.4M |
| SG&A Expense | — | $32.1M | $23.1M | $18.5M |
| Operating Income | — | $-41.3M | $-33.1M | $-28.7M |
| Operating Margin | — | -256.3% | -309.6% | -398.0% |
| Interest Expense | — | $394.0K | $600.0K | — |
| Pretax Income | — | $-42.3M | $-27.8M | $-28.5M |
| Income Tax Expense | — | $252.0K | $-2.0K | $-128.0K |
| Net Income | — | $-42.6M | $-27.8M | $-28.3M |
| Net Margin | — | -264.4% | -260.4% | -393.4% |
| EPS (Basic) | — | $1.41 | $1.12 | $1.34 |
| EPS (Diluted) | — | $1.41 | $1.12 | $1.34 |
| Shares Outstanding (Basic) | 36.3M | 30.2M | 24.8M | 21.2M |
| Shares Outstanding (Diluted) | 36.3M | 30.2M | 24.8M | 21.2M |
| Dividends Per Share | — | — | — | — |